Delving into the Latest Updates on TX-103 with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

B7-H3/CD276 Chimeric Antigen Receptor T-Cell (Fuzhou Tcelltech Biological), B7-H3/CD276嵌合抗原受体T细胞（福州拓新天成生物）, TX-103-CAR-T

+ [3]

Target

CD276

Mechanism

CD276 inhibitors(CD276 antigen inhibitors)

Therapeutic Areas

NeoplasmsNervous System Diseases

Active Indication

High grade gliomaRecurrent Malignant GliomaWHO Grade II Glioma+ [2]

Inactive Indication-

Originator Organization

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.

Active Organization

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

Start Date01 Jun 2024

Sponsor / Collaborator

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.

[+1]

ChiCTR2000040261 / RecruitingEarly Phase 1IIT

Clinical trial of TX103-CAR-T cells in the treatment of abdominal metastatic malignant tumor

Start Date12 Dec 2019

Sponsor / Collaborator

Fujian Medical University

100 Clinical Results associated with TX-103

Login to view more data

100 Translational Medicine associated with TX-103

Login to view more data

100 Patents (Medical) associated with TX-103

Login to view more data

2

Literatures (Medical) associated with TX-103

01 Apr 2018·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT

Article

Author: Hirochika, Rei ; Naito, Keisuke ; Shibuya, Kazuko ; Shibuya, Akira ; Nakamura, Yuho ; Komori, Daisuke ; Yamashita-Kanemaru, Yumi

T cell immunoglobulin and ITIM domains (TIGIT) is an inhibitory immunoreceptor expressed on NK cells, effector and memory T cells, and regulatory T cells (Tregs). The ligands for TIGIT are CD155 (PVR) and CD112 (PVRL2, nectin-2), which are broadly expressed on hematopoietic cells and nonhematopoietic cells. TIGIT negatively regulates antitumor responses, but promotes autoimmune reaction. Although neutralizing anti-human TIGIT mAbs are under clinical trials for cancers, how the blockade of TIGIT interaction with the ligands shows tumor immunity still remains unclear. Although analyses of mouse tumor model using a neutralizing anti-mouse TIGIT (mTIGIT) mAbs should be useful to address this issue, there are limitations to this type of studies due to unavailability of neutralizing anti-mTIGIT mAbs. In this study, we generated five clones of anti-mTIGIT mAbs, designated TX99, TX100, TX103, TX104, and TX105. We show that TX99 and TX100 showed the strongest binding to TIGIT. We also show that TX99 interfered with the interaction between TIGIT and CD155 and increased NK cell-mediated cytotoxicity against CD155-expressing RMA-S cells. Thus, TX99 is a unique neutralizing mAb that can be used for studies of mTIGIT functions.

International Journal of Molecular Sciences

B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?

Review

Author: Graziano, Paolo ; Malapelle, Umberto ; Di Micco, Martina Concetta ; Russo, Alessandro ; Parente, Paola ; Pepe, Francesco ; Rossi, Antonio ; Clemente, Celeste

The striking clinical outcomes of antibody-based immunotherapy, through the inhibitors of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) axis, have driven research aimed at identifying further clinically relevant tumor antigens that can serve as targets in solid tumors. B7 homolog 3 protein (B7-H3, also known as CD276) is a member of the B7 family overexpressed in tumor tissues, including non-small cell lung cancer (NSCLC), while showing limited expression in normal tissues, becoming an attractive and promising target for cancer immunotherapy. B7-H3 expression in tumors has been demonstrated to be associated with poor prognosis. In addition to its role in immune modulation, B7-H3 also promotes pro-tumorigenic functions such as tumor migration, invasion, metastases, resistance, and metabolism. In this review, we will provide an overview of this newly characterized immune checkpoint molecule and its development in the management of metastatic NSCLC.

100 Deals associated with TX-103

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
High grade glioma	Phase 1	CN	Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.	01 Jun 2024
Recurrent Malignant Glioma	Phase 1	CN	Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.	01 Jun 2024
WHO Grade II Glioma	Phase 1	CN	Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.	01 Jun 2024
Advanced Malignant Solid Neoplasm	Phase 1	CN	Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.	30 Jan 2024
Malignant glioma of brain	IND Approval	US	Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.	30 Sep 2023